Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy

In the second bit of bad news for Dr. Reddy's Laboratories ($RDY) in days, the company said on Tuesday that a U.S. federal court had temporarily barred sales of its generic of AstraZeneca's ($AZN) blockbuster heartburn drug Nexium in the U.S., Reuters reports. The order came after the U.K. drugmaker objected to the Indian company's product using the purple color that has come to distinguish AstraZeneca's branded drug. Dr. Reddy's launched its generic Nexium in September after weeks of delay because it had to move production to a different plant after the FDA uncovered GMP issues at the facility where it would be made. The Indian drugmaker said on Friday that the FDA had sent it a warning letter for three of its plants. Story | More

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.